Replies to post #118502 on Anavex Life Sciences Corp (AVXL)

[blu_1]

The problem is that the patients enrolling in trial most likely have been on donepezil for some time, probably years. After 3-12 months, donepezil has "shot its wad" so to speak. In the mice preclinical trial, synergy was observed. The mice went on donepezil FOR THE FIRST TIME at the same time they were put on 2-73. However, in the clinical trial, the 25 patients on donepezil probably weren't just starting it for the first time at the start of the trial. Maybe that is why in the clinical trial synergy was not observed? Also, I do not think the dose of 2-73 and donepezil given in the preclinical trial was equivalent to the doses given in the clinical trial.